FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3029518199> ?p ?o ?g. }

• W3029518199 endingPage "821" @default.
• W3029518199 startingPage "818" @default.
• W3029518199 abstract "ObjectiveTo explore clinical efficacy and safety of Tongfeng decoction combined with celecoxib for the acute gouty arthritis of damp-heat with blood stasis type.MethodsAccording to the random indicator method, 193 of patients with acute gouty arthritis of damp-heat with blood stasis type in our hospital from 2014 January to January 2017 were divided into control group (n=96) and treatment group (n=97). Patients of control group were treated with celecoxib, while treatment group were treated with Tongfeng decoction combined with celecoxib. The two groups were treated for 14 days. Clinical curative effect was evaluated after treatment. The joint pain score, joint function score and quality of life score of the two groups before and after treatment were compared. The BUA, ESR, DD, IL-1 and CRP of the two groups before and after treatment were compared. The adverse reactions of the two groups during the treatment were compared.ResultsTotal effective rate of observation group was 93.81% (91/97), which was significantly higher than the control group 73.96% (71/96), and the difference was statistically significant (χ2=14.109, P<0.01). After treatment, the joint pain (1.1 ± 0.4 vs. 2.4 ± 0.8, t=13.984), joint function score (0.7 ± 0.6 vs. 1.3 ± 0.9, t=5.451) in the treatment group were lower than those in the control group (P<0.05). The quality of life score (39.7 ± 9.3 vs. 32.5 ± 8.6, t=5.623) in the treatment group were higher than that in the control group (P<0.05). After treatment, the BUA (302.47 ± 50.72 μmol/L vs. 395.21 ± 69.63 μmol/L, t=10.584), ESR (11.63 ± 4.05 mm/h vs. 24.87 ± 10.49 mm/h, t=11.589), DD (0.43 ± 0.21 mg/L vs. 0.95 ± 0.71 mg/L, t=6.914), IL-1 (12.03 ± 2.62 ng/L vs. 19.31 ± 3.25 ng/L, t=17.140) and CRP (6.11 ± 2.40 mg/L vs. 11.84 ± 5.49 mg/L, t=9.411) in the treatment group were lower than those in the control group (P<0.05). There was no significantly difference of the adverse reaction rates of the two groups during treatment (χ2=0.216, P=0.642).ConclusionsTongfeng decoction combined with celecoxib for treatment of acute gouty arthritis of damp-heat with blood stasis type showed a good efficacy and low adverse reactions, and it can improve the joint function and quality of life, reduce the BUA.Key words: Arthritis, Gouty; Damp-heat with blood stasis type; Tongfeng decoction; Celecoxib; Clinical Study" @default.
• W3029518199 created "2020-06-05" @default.
• W3029518199 creator A5023762288 @default.
• W3029518199 date "2018-09-30" @default.
• W3029518199 modified "2023-09-23" @default.
• W3029518199 title "Clinical observation of Tongfeng decoction combined with celecoxib for the acute gouty arthritis with damp-heat and blood stasis type" @default.
• W3029518199 doi "https://doi.org/10.3760/cma.j.issn.1673-4246.2018.09.007" @default.
• W3029518199 hasPublicationYear "2018" @default.
• W3029518199 type Work @default.
• W3029518199 sameAs 3029518199 @default.
• W3029518199 citedByCount "0" @default.
• W3029518199 crossrefType "journal-article" @default.
• W3029518199 hasAuthorship W3029518199A5023762288 @default.
• W3029518199 hasConcept C126322002 @default.
• W3029518199 hasConcept C141071460 @default.
• W3029518199 hasConcept C142724271 @default.
• W3029518199 hasConcept C188947578 @default.
• W3029518199 hasConcept C190409667 @default.
• W3029518199 hasConcept C204787440 @default.
• W3029518199 hasConcept C2776379591 @default.
• W3029518199 hasConcept C2776467144 @default.
• W3029518199 hasConcept C2777077863 @default.
• W3029518199 hasConcept C2992440585 @default.
• W3029518199 hasConcept C71924100 @default.
• W3029518199 hasConcept C90924648 @default.
• W3029518199 hasConceptScore W3029518199C126322002 @default.
• W3029518199 hasConceptScore W3029518199C141071460 @default.
• W3029518199 hasConceptScore W3029518199C142724271 @default.
• W3029518199 hasConceptScore W3029518199C188947578 @default.
• W3029518199 hasConceptScore W3029518199C190409667 @default.
• W3029518199 hasConceptScore W3029518199C204787440 @default.
• W3029518199 hasConceptScore W3029518199C2776379591 @default.
• W3029518199 hasConceptScore W3029518199C2776467144 @default.
• W3029518199 hasConceptScore W3029518199C2777077863 @default.
• W3029518199 hasConceptScore W3029518199C2992440585 @default.
• W3029518199 hasConceptScore W3029518199C71924100 @default.
• W3029518199 hasConceptScore W3029518199C90924648 @default.
• W3029518199 hasIssue "9" @default.
• W3029518199 hasLocation W30295181991 @default.
• W3029518199 hasOpenAccess W3029518199 @default.
• W3029518199 hasPrimaryLocation W30295181991 @default.
• W3029518199 hasRelatedWork W2355983265 @default.
• W3029518199 hasRelatedWork W2359519171 @default.
• W3029518199 hasRelatedWork W2386933061 @default.
• W3029518199 hasRelatedWork W2898112675 @default.
• W3029518199 hasRelatedWork W3028683760 @default.
• W3029518199 hasRelatedWork W3029208260 @default.
• W3029518199 hasRelatedWork W3029272727 @default.
• W3029518199 hasRelatedWork W3029338469 @default.
• W3029518199 hasRelatedWork W3029505174 @default.
• W3029518199 hasRelatedWork W3029619854 @default.
• W3029518199 hasRelatedWork W3029706034 @default.
• W3029518199 hasRelatedWork W3030405011 @default.
• W3029518199 hasRelatedWork W3031295518 @default.
• W3029518199 hasRelatedWork W3031507482 @default.
• W3029518199 hasRelatedWork W3031635766 @default.
• W3029518199 hasRelatedWork W3031983370 @default.
• W3029518199 hasRelatedWork W3032113593 @default.
• W3029518199 hasRelatedWork W3032451563 @default.
• W3029518199 hasRelatedWork W3032495358 @default.
• W3029518199 hasRelatedWork W3032577709 @default.
• W3029518199 hasVolume "40" @default.
• W3029518199 isParatext "false" @default.
• W3029518199 isRetracted "false" @default.
• W3029518199 magId "3029518199" @default.
• W3029518199 workType "article" @default.